Following on from information provided to NICE by the company in June 2019, the appraisal of Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1503

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
26 June 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual